Head and neck cancers encompass a wide spectrum of disease, ranging from carcinomas of the upper aerodigestive tract (oral cavity, pharynx, larynx), to tumours of the skin and salivary glands, to sinonasal malignancies.
Lung Cancer Network Malaysia (LCNM), a newly minted non-governmental organization seeks to improve lung cancer awareness in the country. Founders Dr Anand Sachithanandan, a consultant cardiothoracic surgeon, and Dr Tho Lye Mun, a consultant clinical oncologist, sat down with MIMS Doctor to talk about their aspirations for the society and their hopes with regards to lung cancer treatment.
Nasopharyngeal cancer (NPC) is a disease in which cancer cells develop from the tissues of the nasopharynx – an area located behind the nose, just above the back of the throat. Chinese from endemic regions such as Hong Kong and Southern China have the highest risk of getting NPC. NPC is the ninth most common cancer among men in Singapore with the highest incidence in Chinese followed by Malays and is rare among Indians. [Singapore Cancer Registry Annual Registry Report, Trends in Cancer Incidence in Singapore 2015]
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 20190807035449
Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.
Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1cof 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
The eighth most common cancer among women in Singapore, the incidence of thyroid cancer has increased exponentially in the past decades. Fortunately, the most common types of thyroid cancer carry an excellent prognosis and are rarely the cause of mortality if detected early and treated.
At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.
According to the Singapore Cancer Registry, ovarian cancer was the fifth most frequent cancer among women in Singapore and accounted for 5.4 percent of all female cancers diagnosed between 2011 and 2015, with an increasing incidence rate through the last four decades.
Cancer of the corpus uteri (uterine cancer) accounted for nearly 7 percent of all female cancers in Singapore between 2011 and 2015 and was the fourth most frequent female cancer among all Singaporeans.The majority of patients are diagnosed with cancer confined to the uterus and have a 5-year survival rate exceeding 90 percent, while the survival rate of stage IV endometrial cancer is approximately 20 percent. This highlights the importance of recognizing and detecting endometrial cancers early in the natural history.
In this case report, we present the challenges encountered by physicians and cardiologists managing patients with advanced HF, and highlight the broadening spectrum of medical therapies and pathways that comprise contemporary practice.
The syndrome of sensory neuronopathy and detection of anti-Hu antibody in 2010 were very strong indications of the presence of a malignant tumour. In a series of 200 patients positive for anti-Hu, 83.5 percent were found to have cancer, and 90 percent of the cancer cases were small-cell lung cancer.
An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.
Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.
At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.